Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.

Abstract: Method for minimizing the sorption of tear lipids on frequent replacement, or extended-wear, contact lenses, the method comprising (a) contacting the contact lens selected from the group consisting of senofilcon A, lotrafilcon A, lotrafilcon B, and comfilcon A B with a lens care solution for a period of at least three hours to minimize the accumulation of tear lipids on the contact lens. The lens care solution comprises 0.5 ppm to 10 ppm ?-[4-tris(2-hydroxyethyl)-ammonium chloride-2-butenyl]poly[1-dimethyl ammonium chloride-2-butenyl]-?-tris(2-hydroxyethyl) ammonium chloride; citrate, citric acid or a mixture thereof; and 0.005 wt. % to 0.05 wt. % hyaluronic acid. The method also includes (b) inserting the soaked contact lens into one's eye, and (c) repeating steps (a) and (b).

Abstract: A novel pharmaceutical composition, which comprises a therapeutically effective amount of active principle(s) or a pharmaceutically acceptable salt or enantiomer or polymorph thereof, optionally one or more release controlling agent(s) and pharmaceutical acceptable excipient(s) thereof, wherein the composition is formulated to increase the residence time of the said pharmaceutical composition and/or active principle(s) in the gastrointestinal tract. A novel pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is controlled release. A pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is bioadhesive. A pharmaceutical composition comprising: at least two entities wherein one entity is controlled release and the other is bioadhesive All the three compositions are formulated to increase the residence time of active principle(s) in the gastrointestinal tract.

Abstract: An impregnable matrix of plant, animal or synthetic origin or mixtures of same in different proportions, containing an antimicrobial compound uniformly distributed throughout the whole composition, in which the compound is a compound of a transition metal, particularly Cu4SO4(OH)6. In addition, a method is provided for impregnating the matrix with a compound, comprising steps of (a) absorbing or impregnating the antimicrobial compound; (b) centrifuging or pressing or crushing; (c) air drying; and (d) binding and obtaining the active principle. Moreover, the use of the method for the preparation of a matrix having antimicrobial properties and the use of the matrix in the preparation of solid supports or solid materials for cosmetic, pharmaceutical, medical or veterinary use are provided.

Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Abstract: An orally disintegrable tablet, of the present invention, which comprises (i) fine granules having an average particle diameter of 400 ?m or less, which fine granules comprise a composition coated by an enteric coating layer, said composition having 10 weight % or more of an acid-labile physiologically active substance and (ii) an additive, has superior disintegrability or dissolution in the oral cavity so that it can be used for treatment or prevention of various diseases, as an orally disintegrable tablet capable of being administered to the aged or children and easily administered without water. Also, because the tablet of the present invention contains fine granules having the average particle diameter such that it will not impart roughness in mouth, it can be administered easily without discomfort at the administration.

Abstract: The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating fatty acids to quetiapine. Pharmaceutical compositions and methods of synthesizing conjugates of the present technology are also provided. Methods of treating patients with the compositions of the present technology are also provided.

Abstract: Compositions that include a clay such as kaolin dispersed in a liquid such as water may be useful for promoting the clotting of blood. The compositions may be in a liquid, gel, paste, foam, or another form. Uses may include treating a traumatic injury such as in injury caused by a bullet, an explosive, a blade etc., or an injury caused during a medical procedure such as surgery.

Abstract: A family of selectively absorbable/biodegradable, fibrous composite constructs includes different combinations of biostable and absorbable/biodegradable yarns assembled as initially interdependent, load-bearing components, transitioning to exhibit independent functional properties during in vivo end-use. The family of constructs consists of two groups, one group is made of fiber-reinforced composites of high compliance, absorbable matrices of segmented polyaxial copolyesters reinforced with multifilament yarn constructs, which are combinations of ultrahigh molecular weight polyethylene fibers and at least one absorbable/biodegradable fiber selected from silk fibers and multifilament yarns made from linear segmented, l-lactide copolyesters and poly (3-hydroxyalkanoates, are useful in orthopedic, maxillofacial, urological, vascular, hernial repair and tissue engineering applications.

Abstract: Devices for the occlusion of body cavities, such as the embolization of vascular aneurysms and the like, and methods for making and using such devices. The devices may be comprised of novel expansile materials, novel infrastructure design, or both. The devices provided are very flexible and enable deployment with reduced or no damage to bodily tissues, conduits, cavities, etceteras.

Abstract: A drug coating layer which is a drug coating layer having a morphological form including a plurality of elongated bodies having long axes that each crystal of a water-insoluble drug independently has on a substrate surface, in which the long axes of the elongated bodies are nearly linear in shape, and the long axes of the elongated bodies form an angle in a predetermined range with respect to a substrate plane with which the long axis of the elongated body intersects. The drug coating layer can provide low toxicity and a high intravascular stenosis inhibitory effect.

Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Abstract: Methods and compositions are provided which comprise effective amounts of an analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.

Abstract: A planning device generating control data for a treatment apparatus for refraction-correcting ophthalmic surgery is provided, said apparatus using a laser device to separate a corneal volume, which is to be removed for correction, from the surrounding cornea by at least one cut surface in the cornea of an eye, said planning device comprising an interface for receiving corneal data including information on pre-operative cuts which were generated in a previous ophthalmic operation, and computing means for defining a corneal cut surface which confines the corneal volume to be removed, said computing means defining the corneal cut surface on the basis of the corneal data and generating a control dataset for the corneal cut surface for control of the laser device.

Abstract: The present invention comprises systems, methods and devices for the delivery of compositions for occluding or of means for opening conduits. The implantable occlusive material may be delivered pre-formed or in situ cured and, may be a resorbable material that supports tissue ingrowth that eventually replaces the material leaving little or no original material in place. The delivery system is positioned to allow for placement of the occlusive material into the body conduit. Use of delivery systems, methods and devices for re-opening an occluded body conduit are also included.

Abstract: A light-therapeutic composition is disclosed, which can modify the optical characteristics of the skin, thereby increase the effectiveness of the UV-B therapy. The composition according to the invention includes one or more material, which sets the minimum value of wavelength of the light transmitted, one or more material, which is suitable to modify the above-mentioned wavelength value, and increase the transmittance of the skin in a certain wavelength-range, furthermore, optionally an excipient. The composition according to the invention blocks the UV radiation in the wavelength ranging from 280 to 300 nm, and helps the incorporation of the UV radiation by the skin in the wavelength ranging from 310 to 320 nm.

Abstract: Horizontally layered tablets, methods of making the horizontally layered tablets, and tableting equipment capable of producing the horizontally layered tablets are described. The horizontally layered tablets can be produced by simultaneously feeding a segregated flow of different compositions that form the respective layers of the tablet.

Abstract: The present disclosure provides methods for treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. In some embodiments, the method comprises lowering high sensitivity CRP (hs-CRP) levels in a subject including, for example, a subject with a HbA1c value of about 5.00 %-8.50 % or at least about 6.8 %.

Abstract: An irrigant comprising either a hypochlorite compound or a chlorhexidine compound in combination with at least one surfactant and preferably two or more surfactants, including fluorosurfactants, ethoxylates, sulfonates, quaternary ammonium compounds, amine oxides, and combinations thereof, wherein each of the surfactants are capable of complexing with one another.

Abstract: The present invention relates to an oral pharmaceutical fixed dose composition in a form of a dispersible tablet for use in the treatment of tuberculosis, said oral pharmaceutical composition comprising: a) granules comprising isoniazid and at least one intragranular excipient, b) granules comprising rifapentine and at least one intragranular excipient, and c) at least one extragranular excipient, and to its process of preparation.